<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982237</url>
  </required_header>
  <id_info>
    <org_study_id>AK104-303</org_study_id>
    <nct_id>NCT04982237</nct_id>
  </id_info>
  <brief_title>A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus&#xD;
      Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for&#xD;
      Persistent, Recurrent, or Metastatic Cervical Cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival (PFS) assessed by blinded independent central review (BICR) per RECIST v1.1</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Proportion of subjects who have a complete or partial response relative to baseline as assessed by investigator according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response（TTR Per RECIST 1.1 as Assessed by BICR</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed concentrations of AK104</measure>
    <time_frame>From first dose of AK104 through 90 days after last dose of AK104</time_frame>
    <description>The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From first dose of AK104 through 90 days after last dose of AK104</time_frame>
    <description>The immunogenicity of AK104 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>AK104+chemotherapy± bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK104 in combination with cisplatin or carboplatin and paclitaxel± bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+chemotherapy± bevacizumab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in combination with cisplatin or carboplatin and paclitaxel± bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AK104</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>AK104+chemotherapy± bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>AK104+chemotherapy± bevacizumab</arm_group_label>
    <arm_group_label>Placebo+chemotherapy± bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>iv infusion</description>
    <arm_group_label>AK104+chemotherapy± bevacizumab</arm_group_label>
    <arm_group_label>Placebo+chemotherapy± bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>iv infusion</description>
    <arm_group_label>AK104+chemotherapy± bevacizumab</arm_group_label>
    <arm_group_label>Placebo+chemotherapy± bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>iv infusion</description>
    <arm_group_label>AK104+chemotherapy± bevacizumab</arm_group_label>
    <arm_group_label>Placebo+chemotherapy± bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>iv infusion</description>
    <arm_group_label>Placebo+chemotherapy± bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. signs the written informed consent form.&#xD;
&#xD;
          2. Women aged ≥ 18 and ≤ 75 years.&#xD;
&#xD;
          3. ECOG of 0 or 1.&#xD;
&#xD;
          4. Life expectancy ≥ 3 months.&#xD;
&#xD;
          5. Histologically or cytologically confirmed cervical cancer, not amenable to curative&#xD;
             surgery or concurrent chemoradiotherapy.&#xD;
&#xD;
               1. The histological types include squamous cell carcinoma, adenocarcinoma, or&#xD;
                  adenosquamous cell carcinoma;&#xD;
&#xD;
               2. No prior systemic therapy for persistent, recurrent or metastatic ([FIGO] Stage&#xD;
                  IVB) disease.&#xD;
&#xD;
          6. At least one measurable tumor lesion per RECIST v1.1; lesions at sites previously&#xD;
             treated with radiotherapy or other loco-regional therapy are not considered as target&#xD;
             lesions unless the lesion has unequivocal progression or the biopsy is obtained to&#xD;
             confirm maligancy.&#xD;
&#xD;
          7. All subjects must provide archival tumor tissue samples within 2 years prior to&#xD;
             randomization,or fresh tumor tissue samples obtained by biopsy.&#xD;
&#xD;
          8. Subjects must have adequate organ function as assessed in the laboratory tests.&#xD;
&#xD;
          9. Female subjects of childbearing potential must have a negative serum pregnancy test&#xD;
             prior to the first dose. If a female subject of childbearing potential must use&#xD;
             acceptable effective methods of contraception from screening and must agree to&#xD;
             continue these precautions until 120 days after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with other histopathological types of cervical cancer, such as small cell&#xD;
             carcinoma, clear cell carcinoma, sarcoma, etc.&#xD;
&#xD;
          2. Clinically significant hydronephrosis that cannot be relieved by nephrostomy or&#xD;
             ureteral stenting as judged by the Investigator.&#xD;
&#xD;
          3. Presence of nervous system (CNS) metastases or carcinomatous meningitis;&#xD;
&#xD;
          4. Subjects with uncontrollable pleural effusion, pericardial effusion, or ascites&#xD;
             requiring repeated drainage.&#xD;
&#xD;
          5. Patients with other active malignancies within 3 years prior to randomization.&#xD;
&#xD;
          6. Patients who have received other prior chemotherapeutic agents.&#xD;
&#xD;
          7. Any prior treatments targeting the mechanism of tumor immunity, such as&#xD;
             anti-angiogenic therapy (e.g., bevacizumab), immune checkpoint inhibitors (e.g.,&#xD;
             anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.), or therapy&#xD;
             against immune costimulatory factors (e.g., antibodies directed against ICOS, CD40,&#xD;
             CD137, GITR, OX40 targets, etc).&#xD;
&#xD;
          8. Major surgical treatment, open biopsy or significant trauma within 4 weeks prior to&#xD;
             randomization; or elective major surgical treatment required during the study.&#xD;
&#xD;
          9. Active or potentially recurrent autoimmune disease.&#xD;
&#xD;
         10. Subjects who require systemic treatment with glucocorticoid (&gt; 10 mg/day of prednisone&#xD;
             or equivalent glucocorticoid) or other immunosuppressive agents within 14 days prior&#xD;
             to randomization;&#xD;
&#xD;
         11. Use of live vaccines within 4 weeks prior to randomization.&#xD;
&#xD;
         12. Known primary or secondary immunodeficiencies, including testing positive for human&#xD;
             immunodeficiency virus (HIV) antibodies.&#xD;
&#xD;
         13. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem&#xD;
             cell transplantation.&#xD;
&#xD;
         14. Known history of interstitial lung disease or non-infectious pneumonitis; unless&#xD;
             induced by radiation therapies.&#xD;
&#xD;
         15. Serious infections requiring hospitalization.&#xD;
&#xD;
         16. Presence of active infection requiring systemic therapy.&#xD;
&#xD;
         17. Subjects with active hepatitis B and active viral hepatitis C.&#xD;
&#xD;
         18. Active or documented inflammatory bowel diseases, active diverticulitis.&#xD;
&#xD;
         19. Subjects with known history of severe hypersensitivity reactions to other monoclonal&#xD;
             antibodies.&#xD;
&#xD;
         20. Known any contraindication to cisplatin/carboplatin, paclitaxel or allergy to any of&#xD;
             their ingredients.&#xD;
&#xD;
         21. Pregnant or lactating women.&#xD;
&#xD;
         22. Any condition that, in the opinion of the Investigator, may result in a risk when&#xD;
             receiving the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohua Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ting liu</last_name>
    <phone>18601224898</phone>
    <email>ting01.liu@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital ,Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Hospital School Of Medicine Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital,Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>20000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Xiaohua Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

